Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease

JAMA Neurology Author Interviews
16/12/2019 29 min
Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease

Listen "Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease"

Descargar episodio Ver en sitio original

Episode Synopsis

Interview with Charbel Moussa, MD, PhD, author of Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease: A Phase 2 Randomized Clinical Trial

More episodes of the podcast JAMA Neurology Author Interviews

Hemorrhage and Risk Factors in Unruptured Brain AVM 06/10/2025
Intravenous Argatroban or Eptifibatide and Mechanical Thrombectomy 18/08/2025
GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension 14/07/2025
Prognostic Factors for Multiple Sclerosis Symptoms in Radiologically Isolated Syndrome 02/06/2025
Fremanezumab for the Treatment of Migraine and Major Depressive Disorder 05/05/2025
Optimal Delay Time to Initiate Anticoagulation After AF-Associated Ischemic Stroke 31/03/2025
Location and Timing of Recurrent, Nontraumatic Intracerebral Hemorrhage 03/03/2025
Cardiovascular Safety of Anti-CGRP Monoclonal Antibodies in Older Adults or Adults With Disability With Migraine 06/01/2025
β-Blocker Use and Delayed Onset and Progression of Huntington Disease 02/12/2024
Alzheimer Disease as a Clinical-Biological Construct 01/11/2024
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA